Home | About IPJ | Editorial board | Ahead of print | Current Issue | Archives | Instructions | Contact us |   Login 
Industrial Psychiatry Journal
Search Articles   
    
Advanced search   
 
SHORT COMMUNICATION
Year : 2018  |  Volume : 27  |  Issue : 1  |  Page : 154-157

Flibanserin: A controversial drug for female hypoactive sexual desire disorder


1 Department of Obstetrics and Gynecology, IPGME and R and SSKM Hospital, Kolkata, West Bengal, India, Kolkata
2 Department of Cardiology, IPGME and R and SSKM Hospital, Kolkata, West Bengal, India, Kolkata

Correspondence Address:
Dr. Rakesh Agarwal
IPGME and R and SSKM Hospital, AJC Bose Road, P.S-Bhowanipur, Kolkata - 700 020, West Bengal
Kolkata
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ipj.ipj_20_16

Rights and Permissions

Sexual functioning is an integral part of human life. Female sexual dysfunction (FSD) adversely affects quality of life and general well-being. The Food and Drug Administration recently approved flibanserin, for treatment of female hypoactive sexual desire disorder (HSDD), regarded as the most common FSD, amid great controversy. A novel multifunctional serotonin agonist and antagonist, flibanserin, has been shown to be efficacious in treating HSDD but with a rather tenacious side effect profile. We review this interesting drug in its entirety. Data for the article were collected by reviewing articles on PubMed, the drug (Addyi) website, and related websites on the internet.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed197    
    Printed1    
    Emailed0    
    PDF Downloaded6    
    Comments [Add]    

Recommend this journal